News
05-21-2010, 04:40 AM
Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
More... (http://www.news-medical.net/news/20100521/Nektar-Therapeutics-to-present-data-of-NKTR-102-Phase-2-clinical-trial-in-ovarian-cancer-at-46th-ASCO.aspx)
More... (http://www.news-medical.net/news/20100521/Nektar-Therapeutics-to-present-data-of-NKTR-102-Phase-2-clinical-trial-in-ovarian-cancer-at-46th-ASCO.aspx)